FDA's McClellan Calls for More Sharing of Drug R&D Costs

FDA’s McClellan Calls for More Sharing of Drug R&D Costs
The U.S. is bearing a disproportionate share of drug research and development costs for medicines used globally, FDA commissioner Mark McClellan said Thursday.

He called for more equitable cost sharing and price setting. ‘If we do not find better ways to share the burden of developing new drugs and biologics, all of us will suffer’

BIOTECH THAWS OUT

BIOTECH THAWS OUT:
“Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology stocks. A dozen have announced plans this quarter to launch initial public stock offerings (IPOs), while nearly as many more hope to raise money through follow-on bids. The upturn, if it persists, may help rescue a sector where limited cash flow has precipitated major cutbacks and consolidation.”